| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| LeonaBio Inc. | Fosgonimeton (ATH-1017) - (LIFT-AD) | Alzheimer’s disease | Phase 2/3 | Data Released | Intravenous | Neurology |
| LeonaBio Inc. | Fosgonimeton - (OLEX) | Alzheimer's Disease | Phase 2/3 | Trial Planned | Oral | Neurology |
| LeonaBio Inc. | ATH-1017 - (ACT-AD) | Mild-to-moderate Alzheimer's disease | Phase 2 | Data Released | Intravenous | Neurology |
| LeonaBio Inc. | Fosgonimeton (ATH-1017) - (SHAPE) | Parkinson’s disease dementia | Phase 2 | Data Released | Intravenous | Neurology |
| Lexicon Pharmaceuticals Inc. | Zynquista (sotagliflozin) | Type 1 Diabetes and chronic kidney disease (CKD) | NDA Filing | Ongoing | Oral | Endocrinology |
| Lexicon Pharmaceuticals Inc. | Sotagliflozin - (SONATA-HCM) | Hypertrophic cardiomyopathy (HCM) | Phase 3 | Ongoing | Oral | Cardiology |
| Lexicon Pharmaceuticals Inc. | Sotagliflozin - (SOTA-INS CGM) | Basal Insulin-Treated Type 2 Diabetes | Phase 3 | Data Released | Oral | Endocrinology |
| Lexicon Pharmaceuticals Inc. | Sotagliflozin - (SOLOIST-WHF) | Type 2 diabetes | Phase 3 | Data Released | Oral | Endocrinology |